Zimmer Biomet (NYSE:ZBH) said today that it won FDA 510(k) clearance for its robotic Rosa One Spine System intended for use in robotically assisted minimally invasive complex spine procedures.

The Warsaw, Ind.-based company touted that the Rosa One Spine combines robotics and navigation alongside real-time patient dynamic tracking capabilities.

The system also features 3D intraoperative planning software and a suite of navigation technologies intended to improve implants, instrument placement accuracy and predictability, Zimmer Biomet said.

“Rosa One Spine functions as a dual robotics and navigation technology solution for minimally invasive and complex thoracolumbar spine procedures. We are extremely excited about the addition of Rosa One Spine to our already released Rosa One Brain and Rosa Knee systems,” spine, CMF and thoracic surgery assisting tech group prez Aure Bruneau said in a press release.

Zimmer Biomet said that the Rosa One Spine system is available on the same platform as its Rosa One Brain and Rosa One Knee system, making Zimmer Biomet the only company with a robotic platform intended for neurosurgical, spinal and knee pathologies. Both the Rosa One Brain and Rosa One Knee system have already received FDA 510(k) clearance.

Last month, Zimmer Biomet saw shares rise after the medical device maker beat expectations on Wall Street with its fourth quarter and full year 2018 earnings results.